Browse studies

Find your next paid study

6 recruiting studies matching your filters

A Randomized Phase II Trial Comparing Daratumumab-Bortezomib-Dexamethasone Versus Cyclophosphamide-Bortezomib-Dexamethasone in Newly Diagnosed Multiple Myeloma With Light Chain Cast Nephropathy (LCCN)

This study is being done to answer the following question: Can the addition of daratumumab-hyaluronidase to the usual treatment of bortezomib and dexamethason…

Myeloma Multiple

Estimated

~$10 – $7,500

Eastern Cooperative Oncology GroupNCT07085728

Phase 1

A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractor…

Multiple Myeloma in RelapseMyeloma MultipleMultiple Myeloma Progression+11 more

Estimated

~$10 – $8,750

Kelonia Therapeutics, Inc.NCT07075185

Phase 1

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MM…

Multiple MyelomaMyelomaMyeloma Multiple

Estimated

~$10 – $8,750

K36 Therapeutics, Inc.NCT05651932

Phase 2

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant mainten…

Myeloma Multiple

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT05091372

Phase 2

Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial

This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived…

Breast CancerSarcomaGastric Cancer+19 more

Estimated

~$10 – $6,250

University of California, IrvineNCT06580002

Phase 2

Phase 2, Single-Arm, Non-Inferiority Study Of Limited-Duration Teclistamab For Relapsed Refractory Multiple Myeloma

This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myelo…

Myeloma Multiple

Estimated

~$10 – $6,250

Abramson Cancer Center at Penn MedicineNCT05932680